Effect of Zidovudine on Serum Human Immunodeficiency Virus Core Antigen Levels: Results From a Placebo-Controlled Trial

Richard E. Chaisson, Michael D. Leuther, Jean Pierre Allain, Sandra Nusinoff Lehrman, Gloria S. Boone, David Feigal, Paul Volberding

Research output: Contribution to journalArticlepeer-review

Abstract

We assessed the effect of antiviral therapy on serum human immunodeficiency virus core antigen (HIV-Ag) levels in patients enrolled in the phase II trial on zidovudine for acquired immunodeficiency syndrome (AIDS) and AIDS—related complex. Human immunodeficiency virus core antigen was detected in 45% of subjects at entry (59% with AIDS and 37% of patients with AIDS—related complex). Median HIV-Ag levels in zidovudine-treated subjects fell from 111 pg/mL at entry to 46 pg/mL at four weeks, while levels in placebo recipients did not change significantly. Decline in HIV-Ag in zidovudine recipients was sustained through 16 weeks of treatment and was significantly different from the placebo group. Anti—p24 antibody levels did not change in either group. We conclude that in patients with HIV-antigenemia changes in HIV-Ag level are an important marker of anti—retroviral activity.

Original languageEnglish (US)
Pages (from-to)2151-2153
Number of pages3
JournalArchives of internal medicine
Volume148
Issue number10
DOIs
StatePublished - Oct 1988

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Effect of Zidovudine on Serum Human Immunodeficiency Virus Core Antigen Levels: Results From a Placebo-Controlled Trial'. Together they form a unique fingerprint.

Cite this